A Pilot Study of the Efficacy and Tolerability of Bupropion Extended Release (Wellbutrin XL) for the Treatment of Major Depressive Disorder in Women With Breast Cancer
This is research study for women diagnosed with breast cancer and major depression. Women
with breast cancer who are depressed may report greater pain, poorer quality of life and
worse overall functioning than those without depression. The study will determine whether or
not bupropion extended release (Wellbutrin XLTM) is useful in lessening the symptoms of
depression in women with breast cancer. One reason for conducting this research with
bupropion extended release (Wellbutrin XLTM) instead of another antidepressant is because
bupropion has a lower likelihood of causing the side effects of weight gain, sexual
dysfunction, and fatigue, which may be important for women with breast cancer and may even
have a beneficial effect on these symptoms.
Bupropion extended release (Wellbutrin XL™)is approved by the United States Food and Drug
Administration (FDA) for the treatment of major depression.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the efficacy of bupropion extended release (Wellbutrin XL™) in the treatment of Major Depressive Disorder in women with breast cancer.
Rajnish Mago, MD
Thomas Jefferson University Department of Psychiatry and Human Behavior
United States: Food and Drug Administration
|Thomas Jefferson University, Department of Psychiatry||Philadelphia, Pennsylvania 19107|